Education
About Us
Working with TipRanks
Follow Us
Poxel SA (FR:POXEL)
:POXEL
POXEL Stock Chart & Stats
€0.24
-€0.02(-8.98%)
At close: 4:00 PM EST
€0.24
-€0.02(-8.98%)
Day’s Range― - ―
52-Week Range€0.12 - €0.83
Previous CloseN/A
Volume292.16K
Average Volume (3M)288.32K
Market Cap
€12.84M
Enterprise Value€0.00
Total Cash (Recent Filing)€3.66M
Total Debt (Recent Filing)€69.71M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding53,758,167
10 Day Avg. Volume262,495
30 Day Avg. Volume288,318
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
POXEL FAQ
What was Poxel SA’s price range in the past 12 months?
Poxel SA lowest stock price was €0.12 and its highest was €0.83 in the past 12 months.
What is Poxel SA’s market cap?
Poxel SA’s market cap is €12.84M.
When is Poxel SA’s upcoming earnings report date?
Poxel SA’s upcoming earnings report date is Mar 25, 2026 which is in 85 days.
How were Poxel SA’s earnings last quarter?
Poxel SA released its earnings results on Sep 23, 2025. The company reported -€0.049 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.049.
Is Poxel SA overvalued?
According to Wall Street analysts Poxel SA’s price is currently Overvalued.
Does Poxel SA pay dividends?
Poxel SA does not currently pay dividends.
What is Poxel SA’s EPS estimate?
Poxel SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poxel SA have?
Poxel SA has 53,758,167 shares outstanding.
What happened to Poxel SA’s price movement after its last earnings report?
Poxel SA reported an EPS of -€0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Poxel SA?
Currently, no hedge funds are holding shares in FR:POXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.